A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
Saved in:
| Title: | A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. |
|---|---|
| Authors: | Jazieh K; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Molina J; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Allred J; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Yin J; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Reid J; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Goetz M; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Lim VS; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Kaufmann SH; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Adjei A; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. adjei.alex@mayo.edu. |
| Source: | Investigational new drugs [Invest New Drugs] 2019 Apr; Vol. 37 (2), pp. 307-314. Date of Electronic Publication: 2018 Aug 31. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 30171497 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Jazieh+K%22">Jazieh K</searchLink>; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.<br /><searchLink fieldCode="AU" term="%22Molina+J%22">Molina J</searchLink>; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.<br /><searchLink fieldCode="AU" term="%22Allred+J%22">Allred J</searchLink>; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.<br /><searchLink fieldCode="AU" term="%22Yin+J%22">Yin J</searchLink>; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.<br /><searchLink fieldCode="AU" term="%22Reid+J%22">Reid J</searchLink>; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.<br /><searchLink fieldCode="AU" term="%22Goetz+M%22">Goetz M</searchLink>; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.<br /><searchLink fieldCode="AU" term="%22Lim+VS%22">Lim VS</searchLink>; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.<br /><searchLink fieldCode="AU" term="%22Kaufmann+SH%22">Kaufmann SH</searchLink>; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.<br /><searchLink fieldCode="AU" term="%22Adjei+A%22">Adjei A</searchLink>; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. adjei.alex@mayo.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2019 Apr; Vol. 37 (2), pp. 307-314. <i>Date of Electronic Publication: </i>2018 Aug 31. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30171497 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10637-018-0662-1 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 307 Titles: – TitleFull: A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Jazieh K – PersonEntity: Name: NameFull: Molina J – PersonEntity: Name: NameFull: Allred J – PersonEntity: Name: NameFull: Yin J – PersonEntity: Name: NameFull: Reid J – PersonEntity: Name: NameFull: Goetz M – PersonEntity: Name: NameFull: Lim VS – PersonEntity: Name: NameFull: Kaufmann SH – PersonEntity: Name: NameFull: Adjei A IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2019 Apr Type: published Y: 2019 Identifiers: – Type: issn-electronic Value: 1573-0646 Numbering: – Type: volume Value: 37 – Type: issue Value: 2 Titles: – TitleFull: Investigational new drugs Type: main |
| ResultId | 1 |
